Mutabilis
  • About us
    • Company overview
    • Management
    • Scientific Advisory Board
    • Partners
  • R&D
    • Pipeline
  • News
  • Contact
    • Localization

  • Home
  • Blog
  • All
  • News

November 21, 2013 : Mutabilis published on HIV

By: admutabilis | Tags: | Comments: 0

“Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.”

READ MORE

March 14, 2013: Mutabilis publishes on G-

By: admutabilis | Tags: | Comments: 0

“Vectorization efforts to increase Gram-negative intracellular drug concentration: a case study on HldE-K inhibitors.”

READ MORE

February 28, 2013: Mutabilis publishes on G-

By: admutabilis | Tags: | Comments: 0

“Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.”

READ MORE

February 28, 2013: Mutabilis publishes on G-

By: admutabilis | Tags: | Comments: 0

“Structural-functional studies of Burkholderia cenocepacia D-glycero-β-D-manno-heptose 7-phosphate kinase (HldA) and characterization of inhibitors with antibiotic adjuvant and antivirulence properties.”

READ MORE
  • « Previous
  • 1
  • 2
  • 3
  • 4

MUTABILIS


Biocitech Park, 102 avenue Gaston Roussel, 93230 Romainville, France info@mutabilis.fr


Mutabilis is a biopharmaceutical company specialized in research and development of anti-infectious treatments.


Legal notice / Contact us